Segment Information (Tables)

9 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31,
(in millions)	2021		2020
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	34,903	$	34,899
Nuclear and Precision Health Solutions	201		213
Pharmaceutical segment revenue	35,104		35,112
Medical distribution and products (3)	3,638		3,539
Cardinal Health at-Home Solutions	536		512
Medical segment revenue	4,174		4,051
Total segment revenue	39,278		39,163
Corporate (4)	(3)		(6)
Total revenue	$	39,275	$	39,157

	Nine Months Ended March 31,
(in millions)	2021		2020
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	106,859	$	103,612
Nuclear and Precision Health Solutions	593		642
Pharmaceutical segment revenue	107,452		104,254
Medical distribution and products (3)	10,805		10,483
Cardinal Health at-Home Solutions	1,636		1,508
Medical segment revenue	12,441		11,991
Total segment revenue	119,893		116,245
Corporate (4)	(12)		(12)
Total revenue	$	119,881	$	116,233

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]

The following tables present revenue by geographic area:

	Three Months Ended March 31,
(in millions)	2021		2020
United States	$	38,089	$	38,073
International	1,189		1,090
Total segment revenue	39,278		39,163
Corporate (1)	(3)		(6)
Total revenue	$	39,275	$	39,157

	Nine Months Ended March 31,
(in millions)	2021		2020
United States	$	116,425	$	113,053
International	3,468		3,192
Total segment revenue	119,893		116,245
Corporate (1)	(12)		(12)
Total revenue	$	119,881	$	116,233

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:

	Three Months Ended March 31,
(in millions)	2021		2020
Pharmaceutical	$	511	$	534
Medical	174		178
Total segment profit	685		712
Corporate	(212)		(150)
Total operating earnings	$	473	$	562

	Nine Months Ended March 31,
(in millions)	2021		2020
Pharmaceutical	$	1,326	$	1,394
Medical	640		543
Total segment profit	1,966		1,937
Corporate	(1,656)		(6,305)
Total operating earnings/(loss)	$	310	$	(4,368)

Assets by Reportable Segment

The following table presents total assets for each reportable segment and Corporate at:

(in millions)	March 31, 2021		June 30, 2020
Pharmaceutical	$	23,078	$	22,398
Medical (1)	15,280		14,691
Corporate	5,516		3,677
Total assets	$	43,874	$	40,766

(1)Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March 31, 2021.